The Five Tests of HealthTech Readiness
A promising demonstration can obscure the clinical, regulatory and commercial questions that will eventually determine whether a health technology can be used at scale.
The first twenty minutes of a healthtech presentation can be remarkably persuasive. The interface is polished, the data flow smoothly and the artificial intelligence produces its answer within seconds. A patient application sends the right reminder. A remote-monitoring platform identifies a change in risk. A clinical decision-support tool highlights the next action for a doctor to consider.
The questions tend to become harder when the conversation turns to implementation. Where will the output appear in the clinical workflow? Who will review it? How often will it generate an alert? What happens when the data are incomplete? Which claims will require regulatory clearance? What evidence will persuade a hospital, pharmaceutical company or payer to adopt it?
These questions are sometimes postponed until a company approaches a major customer, investor or commercial partner. By then, the technology may have been built around assumptions that are expensive to change.
This is why life-sciences leaders need a broader definition of healthtech readiness. Technical performance matters, but it is one part of a system that also includes clinical usefulness, regulation, evidence, intellectual property, cybersecurity and a credible route to adoption.
Begin with the clinical setting
A health technology enters an existing environment of people, responsibilities, habits and constraints. Its success depends on how well it fits that environment.
Consider an accurate clinical alert that reaches a physician after the treatment decision has already been made. A remote-monitoring platform may identify every small change in a patient’s condition, yet create more alerts than a nursing team can reasonably review. A patient application may be easy to download and still require more sustained attention than most users can provide.
Each product works as designed. The difficulty lies in the setting in which it is expected to work.
Clinical assessment should begin with the specific problem, the people affected by it and the point in the care pathway where intervention is possible. It should examine who receives the information, what action follows and who remains responsible when the recommendation is incomplete, delayed or incorrect.
This requires direct input from clinicians and patients as well as an understanding of hospital operations, staffing, infrastructure and variations in practice. A product designed around an idealized care pathway may perform very differently in a crowded clinic with limited time and incomplete records.
For a life-sciences company considering a partnership, the clinical question should be precise. What useful change will this technology make in the management of a patient, the work of an HCP or the delivery of a program?
Establish the regulatory path early for HealthTech readiness
The intended use of a product affects almost every decision that follows.
Software that stores or displays information may have a different regulatory position from software that interprets patient data or recommends a clinical action. A feature intended for use by a trained professional may be assessed differently when it is placed directly in the hands of a patient or caregiver.
In the United States, the FDA’s January 2026 guidance on clinical decision-support software explains the circumstances in which certain software functions may fall outside the definition of a medical device. It also confirms that software functions meeting the device definition remain subject to the relevant digital-health policies. The function, intended user and ability to review the basis of a recommendation all matter. (FDA Clinical Decision Support Software Guidance)
This makes product language unusually important. A new claim, user group or feature can change the regulatory analysis and the evidence that will be expected.
Regulatory specialists should therefore be involved while the intended use and product architecture are still being shaped. Their early involvement can help the development team choose an appropriate route and document the decisions that support it. Waiting until the product is complete leaves fewer options and may create a need for additional validation or redevelopment.
The analysis also needs to reflect the markets in which the company plans to operate. A workable route in one country cannot be assumed to apply elsewhere.
Decide what evidence the customer will need
Early healthtech studies often concentrate on the measures that are easiest to collect. These may include model accuracy, user satisfaction, number of registrations or time spent on the platform.
Such findings can be useful. Their value depends on the claim being made and the decision they are meant to support.
A hospital may want evidence that a product improves workflow or patient care. A pharmaceutical company may be interested in treatment initiation, persistence, evidence generation or HCP engagement. A payer may focus on utilization and cost. A regulator may require a different set of performance and safety measures.
These audiences are asking related questions, but they are seldom asking the same question.
NICE’s Evidence Standards Framework for digital health technologies provides a useful approach to this problem.
It helps developers and evaluators classify a technology and identify the evidence standards relevant to its function. (NICE Evidence Standards Framework)
An evidence plan should begin with the decision the company hopes to secure. The study design, patient population, comparator and outcome measures can then be selected with that decision in mind.
This approach also helps distinguish technical performance from clinical value. A model can identify a pattern accurately without improving a decision. A patient application can achieve high initial engagement without producing sustained use. A successful pilot in one institution may say little about implementation across a wider health system.
Good evidence answers the questions that matter to the intended adopter thus aiding HealthTech readiness.
Examine what the company actually owns
Healthtech companies frequently describe their platforms as proprietary. The word covers many different forms of advantage.
A company may own its software, algorithm or clinical workflow. Its advantage may come from access to a particular dataset, integration with health systems, specialist knowledge or the evidence accumulated through use. Some of these assets can be protected through patents. Others depend on copyright, contracts, trade secrets, data rights or continued execution.
The position becomes less clear when software has been developed by outside contractors, when open-source components carry licensing conditions or when training data were collected under agreements that restrict future use.
Life-sciences leaders should understand which parts of the product the company controls and which parts depend on third parties. They should also consider how easily another organization could reproduce the product and whether the source of advantage will strengthen over time.
The same review should cover public disclosure. Presentations, research papers, demonstrations and investor materials can reveal information that later proves important to an intellectual-property strategy. Early review by qualified patent and legal professionals can preserve options that may otherwise disappear.
Treat cybersecurity as part of product quality
A connected health product rarely operates alone. It may exchange information with patient devices, hospital systems, cloud infrastructure and third-party software. Each connection adds utility and creates another point that requires attention.
Cybersecurity failures can affect privacy, product availability and clinical safety. They can also delay hospital procurement or regulatory review when the necessary documentation and controls were never built into development.
The FDA’s February 2026 guidance on medical-device cybersecurity places cybersecurity within device safety and quality management. It describes secure product development as a lifecycle activity covering design, development, release, support and eventual decommissioning. (FDA Cybersecurity in Medical Devices Guidance)
A readiness assessment should examine what information the product collects, where it travels, who can access it and how the system behaves when a component fails. It should also cover authentication, software updates, third-party dependencies, incident response and recovery.
These decisions affect the architecture of the product. Addressing them early is usually easier than rebuilding security and documentation after a prospective customer has completed its technical review.
Follow the path to adoption
A clinically useful, well-regulated and evidence-supported technology still needs someone to buy it, implement it and maintain it.
In healthcare, these roles are often divided among several organizations and departments. The clinician may use the product, a hospital committee may approve it and another department may fund it. The patient may receive the benefit while the financial return appears elsewhere in the system.
A pharmaceutical company may view the same technology through a different lens. It may support clinical development, medical education, patient services, treatment adherence or the generation of real-world evidence. Each use case brings its own budget, stakeholders and requirements.
A realistic commercialization plan identifies the economic buyer, the implementation owner and the people who will use the product. It accounts for integration, training, customer support, procurement, security review and the time required to move through institutional decision-making.
This work can reveal that the initial market is too broad or that the proposed buyer receives too little of the value. It may also uncover a better entry point, such as a defined patient group, clinical department, pharmaceutical program or health-system partner.
Consider the connections between the five tests
Clinical, regulatory, evidence, intellectual-property and commercial decisions continually influence one another.
A change in the clinical use case can alter the regulatory pathway. The evidence required for adoption may depend on data the company does not yet have the right to use. A hospital integration can introduce new security requirements. A narrower intended use may reduce development complexity while changing the size and economics of the market.
Separate reviews can miss these connections. Clinical advisers, regulatory specialists, evidence experts, IP professionals and commercial leaders may each provide sound advice within their field while working from different assumptions about the product.
A multidisciplinary review brings those assumptions into the same discussion.
The useful output is a practical map of the issues that deserve immediate attention. It should identify the gaps that could change the product, the questions requiring specialist advice and the assumptions that need to be tested. A prioritized 90-day plan can then separate urgent decisions from work that can reasonably wait.
Early-stage technology will always carry uncertainty. Leadership gains an advantage when it can see where that uncertainty sits and what would be required to reduce it.
Before approving the pilot
A life-sciences leadership team considering a healthtech pilot, partnership or investment should be able to explain five things clearly.
It should know where the product fits into care and what change it is expected to produce.
It should understand the intended use and likely regulatory pathway.
It should know what evidence the eventual adopter will require.
It should be satisfied that the company controls the assets on which its advantage depends.
It should also see a credible route through procurement, implementation and continued use.
Unclear answers do not automatically disqualify an early technology. They show where further work is needed before capital and organizational attention are committed.
The attraction of healthtech lies in its ability to address persistent problems in healthcare with new forms of data, intelligence and delivery. Realizing that potential requires more than a strong demonstration. It requires a product that can survive contact with clinical practice.
Heylth’s HealthTech Advisory brings clinical, regulatory, evidence, intellectual-property and commercialization perspectives into product development and partnership decisions.
Explore a HealthTech Readiness Review.
Comments